Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (285)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Editorial (3)
  8. Correspondence (2)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (781)
  2. Department of Medicine (781)
  3. Hematologic Malignancies, Division of (781)
  4. Lymphoma (781)
  5. Survivorship Research (232)
  6. Population Sciences Research Program (186)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (185)
  3. Paul Hamlin (184)
  4. Steven Horwitz (166)
  5. David Straus (162)
  6. Maria Palomba (140)

More People

Years
  1. 2025 (5)
  2. 2024 (30)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (30)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Oxford University Press (31)
  6. Elsevier Inc. (30)

More Publishers

Results (781)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
    Journal Article

    Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • ME-401, a novel, oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ) in early clinical development for B-cell lymphoid malignancies
    Meeting Abstract

    Ghalie, R. G.; Pagel, J. M.; Soumerai, J.; Iasonos, A.; Patel, K.; Moreno, O.; Butler, T.; Zelenetz, A. D.
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma
    Meeting Abstract

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Chronic lymphocytic leukemia: Individualizing treatment approach
    Journal Article

    Zelenetz, A. D.
    Journal of the National Comprehensive Cancer Network (2017)

    Fulltext@MSK | Save
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017
    Journal Article

    Wierda, W. G.; Zelenetz, A. D.; Gordon, L. I.; Abramson, J. S.; Advani, R. H.; Andreadis, C. B.; Bartlett, N.; Byrd, J. C.; Caimi, P.; Fayad, L. E.; more...
    Journal of the National Comprehensive Cancer Network (2017)

    Fulltext@MSK | Save